Skip to main content
Top
Published in: BMC Cancer 1/2020

01-12-2020 | Human Papillomavirus | Research article

The molecular pathogenesis of Trichilemmal carcinoma

Authors: Jeong Hyun Ha, Cheol Lee, Kyu Sang Lee, Chang-sik Pak, Choong-Hyun Sun, Youngil Koh, Hak Chang

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

Trichilemmal carcinoma (TC) is an extremely rare hair follicle tumor. We aimed to explore the genetic abnormalities involved in TC to gain insight into its molecular pathogenesis.

Methods

Data from patients diagnosed with TC within a 12-year period were retrospectively reviewed. Genomic DNA isolated from a formalin-fixed paraffin-embedded (FFPE) tumor tissue block was sequenced and explored for a panel of cancer genes.

Results

DNA was extracted from the FFPE tissue of four patients (50% female; mean age, 51.5 years) diagnosed with TC for analysis. The tumor was located in the head and neck of three patients and in the shoulder of one patient. TP53 mutations (p.Arg213*, p.Arg249Trp, and p.Arg248Gln) were found in three patients. Fusions previously identified in melanoma were detected in two patients (TACC3-FGFR3 and ROS1-GOPC fusions). Other mutations found included NF1-truncating mutation (Arg1362*), NRAS mutation (p.Gln61Lys), TOP1 amplification, and PTEN deletion. Overall, genetic changes found in TC resemble that of other skin cancers, suggesting similar pathogenesis. All patients with TP53 mutations had aggressive clinical course, two who died (OS 93 and 36 months), and one who experienced recurrent relapse.

Conclusions

We reported the genomic variations found in TC, which may give insight into the molecular pathogenesis. Overall, genetic changes found in TC resembled that of other skin cancers, suggesting similar pathogenesis. TP53 mutations was were identified in patients who had an aggressive clinical course. Genetic alterations identified may further suggest the potential treatment options of TC.
Literature
1.
go back to reference Hamman MS, Brian Jiang SI. Management of trichilemmal carcinoma: an update and comprehensive review of the literature. Dermatol Surg. 2014;40:711–7.PubMed Hamman MS, Brian Jiang SI. Management of trichilemmal carcinoma: an update and comprehensive review of the literature. Dermatol Surg. 2014;40:711–7.PubMed
3.
go back to reference Reis JP, Tellechea O, Cunha MF, Baptista AP. Trichilemmal carcinoma: review of 8 cases. J Cutan Pathol. 1993;20:44–9.CrossRef Reis JP, Tellechea O, Cunha MF, Baptista AP. Trichilemmal carcinoma: review of 8 cases. J Cutan Pathol. 1993;20:44–9.CrossRef
4.
go back to reference Boscaino A, Terracciano LM, Donofrio V, Ferrara G, De Rosa G. Tricholemmal carcinoma: a study of seven cases. J Cutan Pathol. 1992;19:94–9.CrossRef Boscaino A, Terracciano LM, Donofrio V, Ferrara G, De Rosa G. Tricholemmal carcinoma: a study of seven cases. J Cutan Pathol. 1992;19:94–9.CrossRef
5.
go back to reference Allee JE, Cotsarelis G, Solky B, Cook JL. Multiply recurrent trichilemmal carcinoma with perineural invasion and cytokeratin 17 positivity. Dermatol Surg. 2003;29:886–9.PubMed Allee JE, Cotsarelis G, Solky B, Cook JL. Multiply recurrent trichilemmal carcinoma with perineural invasion and cytokeratin 17 positivity. Dermatol Surg. 2003;29:886–9.PubMed
6.
go back to reference O'Hare AM, Cooper PH, Parlette HL 3rd. Trichilemmomal carcinoma in a patient with Cowden's disease (multiple hamartoma syndrome). J Am Acad Dermatol. 1997;36:1021–3.CrossRef O'Hare AM, Cooper PH, Parlette HL 3rd. Trichilemmomal carcinoma in a patient with Cowden's disease (multiple hamartoma syndrome). J Am Acad Dermatol. 1997;36:1021–3.CrossRef
7.
go back to reference Oyama N, Kaneko F. Trichilemmal carcinoma arising in seborrheic keratosis: a case report and published work review. J Dermatol. 2008;35:782–5.CrossRef Oyama N, Kaneko F. Trichilemmal carcinoma arising in seborrheic keratosis: a case report and published work review. J Dermatol. 2008;35:782–5.CrossRef
8.
go back to reference Takata M, Rehman I, Rees JL. A trichilemmal carcinoma arising from a proliferating trichilemmal cyst: the loss of the wild-type p53 is a critical event in malignant transformation. Hum Pathol. 1998;29:193–5.CrossRef Takata M, Rehman I, Rees JL. A trichilemmal carcinoma arising from a proliferating trichilemmal cyst: the loss of the wild-type p53 is a critical event in malignant transformation. Hum Pathol. 1998;29:193–5.CrossRef
9.
go back to reference Van der Auwera GA, et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43(11 10):11–33.PubMed Van der Auwera GA, et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43(11 10):11–33.PubMed
10.
go back to reference Wilm A, et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012;40:11189–201.CrossRef Wilm A, et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012;40:11189–201.CrossRef
11.
go back to reference Wei Z, Wang W, Hu P, Lyon GJ, Hakonarson H. SNVer: a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data. Nucleic Acids Res. 2011;39:e132.CrossRef Wei Z, Wang W, Hu P, Lyon GJ, Hakonarson H. SNVer: a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data. Nucleic Acids Res. 2011;39:e132.CrossRef
16.
go back to reference de Oliveira WR, Festa Neto C, Rady PL, Tyring SK. Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol. 2003;17:394–8.CrossRef de Oliveira WR, Festa Neto C, Rady PL, Tyring SK. Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol. 2003;17:394–8.CrossRef
17.
go back to reference Clower RV, Hu Y, Melendy T. Papillomavirus E2 protein interacts with and stimulates human topoisomerase I. Virology. 2006;348:13–8.CrossRef Clower RV, Hu Y, Melendy T. Papillomavirus E2 protein interacts with and stimulates human topoisomerase I. Virology. 2006;348:13–8.CrossRef
18.
go back to reference Patel T, Morrison LK, Rady P, Tyring S. Epidermodysplasia verruciformis and susceptibility to HPV. Dis Markers. 2010;29:199–206.CrossRef Patel T, Morrison LK, Rady P, Tyring S. Epidermodysplasia verruciformis and susceptibility to HPV. Dis Markers. 2010;29:199–206.CrossRef
19.
go back to reference Wallace NA, Robinson K, Howie HL, Galloway DA. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. PLoS Pathog. 2012;8:e1002807.CrossRef Wallace NA, Robinson K, Howie HL, Galloway DA. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. PLoS Pathog. 2012;8:e1002807.CrossRef
20.
go back to reference Prati B, Marangoni B, Boccardo E. Human papillomavirus and genome instability: from productive infection to cancer. Clinics (Sao Paulo). 2018;73(e539s).. Prati B, Marangoni B, Boccardo E. Human papillomavirus and genome instability: from productive infection to cancer. Clinics (Sao Paulo). 2018;73(e539s)..
21.
go back to reference Koncar RF, Feldman R, Bahassi EM, Hashemi Sadraei N. Comparative molecular profiling of HPV-induced squamous cell carcinomas. Cancer Med. 2017;6:1673–85.CrossRef Koncar RF, Feldman R, Bahassi EM, Hashemi Sadraei N. Comparative molecular profiling of HPV-induced squamous cell carcinomas. Cancer Med. 2017;6:1673–85.CrossRef
22.
go back to reference Craig S, Earnshaw CH, Viros A. Ultraviolet light and melanoma. J Pathol. 2018;244:578–85.CrossRef Craig S, Earnshaw CH, Viros A. Ultraviolet light and melanoma. J Pathol. 2018;244:578–85.CrossRef
23.
go back to reference Stahl PL, et al. Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin. J Invest Dermatol. 2011;131:504–8.CrossRef Stahl PL, et al. Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin. J Invest Dermatol. 2011;131:504–8.CrossRef
24.
go back to reference Ragnarsson-Olding BK, Karsberg S, Platz A, Ringborg UK. Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. Melanoma Res. 2002;12:453–63.CrossRef Ragnarsson-Olding BK, Karsberg S, Platz A, Ringborg UK. Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. Melanoma Res. 2002;12:453–63.CrossRef
25.
go back to reference Donovan J. Review of the hair follicle origin hypothesis for basal cell carcinoma. Dermatol Surg. 2009;35:1311–23. Donovan J. Review of the hair follicle origin hypothesis for basal cell carcinoma. Dermatol Surg. 2009;35:1311–23.
26.
go back to reference Youssef KK, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010;12:299–305.CrossRef Youssef KK, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010;12:299–305.CrossRef
27.
go back to reference Lee J, Lee J, Hong SD, Jang KT, Lee SJ. FGFR3-TACC3: a novel gene fusion in malignant melanoma. Precis Future Med. 2018;2:71–5.CrossRef Lee J, Lee J, Hong SD, Jang KT, Lee SJ. FGFR3-TACC3: a novel gene fusion in malignant melanoma. Precis Future Med. 2018;2:71–5.CrossRef
28.
go back to reference Couts KL, et al. Acral lentiginous melanoma harboring a ROS1 gene fusion with clinical response to Entrectinib. Jco Precis Oncol. 2017;1. Couts KL, et al. Acral lentiginous melanoma harboring a ROS1 gene fusion with clinical response to Entrectinib. Jco Precis Oncol. 2017;1.
Metadata
Title
The molecular pathogenesis of Trichilemmal carcinoma
Authors
Jeong Hyun Ha
Cheol Lee
Kyu Sang Lee
Chang-sik Pak
Choong-Hyun Sun
Youngil Koh
Hak Chang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07009-7

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine